UofL Physicians - Surgery401 E. Chestnut St., Suite 710
Louisville, KY 40202
​
Clinical Trials
Dr. Martin is the principal investigator for multiple clinical trials that are investigating new devices, drugs, and treatment combinations
Pivotal Study in HCC:
Radioembolization Oncology trial Utilizing Transarterial Eye90 (ROUTE 90) for the treatment of Hepatocellular Carcinoma (HCC)
​
Indication:
Eye90 microspheres® is intended for use as internal radiation brachytherapy for local tumor control in patients with unresectable Hepatocellular Carcinoma (HCC).
​
Eligible Patients:
-
Confirmed diagnosis of HCC, LIRADS 5 or biopsy
-
One lesion ≥ 2 cm in diameter, no more than 3 lesions
-
Max 3 lesions and single lesion size ≤ 8 cm & sum tumor dimensions of ≤ 12 cm
-
Evidence that > 33% of the total liver volume is disease-free
-
No extra hepatic disease • Child Pugh Class A, ECOG 0-1, BCLC A, B, C
Investigator Initiated Study in HCC:
A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants with Hepatocellular Carcinoma after Complete Radiological Response following Surgical Resection and Local Ablation or Local Ablation Alone
The Study:
IP-001 is an investigational drug used as an intratumoral injection used after ablation that increases the body’s immune response after ablation
Primary Objective:
Evaluate recurrence-free survival (RFS) after curative standard of care ablation or surgical resection with and without IP-001
Key Eligibility
-
Intermediate, High, Very High Risk for Recurrence of HCC
-
Treatment plan with curative ablation or curative surgical resection & ablation
-
No extrahepatic disease
-
ECOG: 0-1
Investigator Initiated Study in Advanced Pancreatic Adenocarcinoma:
Immunotherapy and Irreversible Electroporation in the Treatment of
Locally Advanced Pancreatic Adenocarcinoma
The Study:
Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively.
Primary Objective:
Evaluate efficacy, safety and tolerability of a combined treatment approach to locally advanced pancreatic cancer, utilizing both a local (IRE) and systemic Immuno-therapy.
Key Eligibility
-
Diagnosed with Stage III Pancreatic Cancer
-
Tumor Is measurable
-
Patient is a candidate irreversible electroporation